Jonathan Allan Sells 1,457 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares of the company’s stock, valued at $541,675.70. This represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $31.00 on Friday. Stoke Therapeutics, Inc. has a twelve month low of $11.17 and a twelve month high of $40.22. The stock has a market cap of $1.93 billion, a PE ratio of -11.03 and a beta of 1.17. The firm has a 50-day simple moving average of $31.93 and a 200 day simple moving average of $32.34.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. Research analysts forecast that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

Large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC bought a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $26,000. KBC Group NV bought a new stake in Stoke Therapeutics in the first quarter valued at $36,000. Harbour Investments Inc. grew its position in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC acquired a new position in Stoke Therapeutics during the third quarter worth $41,000. Finally, BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts recently commented on STOK shares. Weiss Ratings lowered Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 price target on the stock. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. BTIG Research restated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a research note on Monday, May 11th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, March 18th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.